Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2021)

Historic Gross Margin for Neurocrine Biosciences (NBIX) over the last 5 years, with Q3 2021 value amounting to 98.58%.

  • Neurocrine Biosciences' Gross Margin fell 3700.0% to 98.58% in Q3 2021 from the same period last year, while for Sep 2021 it was 99.78%, marking a year-over-year increase of 7200.0%. This contributed to the annual value of 99.06% for FY2019, which is 1400.0% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Gross Margin stood at 98.58% for Q3 2021, which was down 3700.0% from 98.93% recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Gross Margin high stood at 99.29% for Q3 2017, and its period low was 98.58% during Q3 2021.
  • Over the past 5 years, Neurocrine Biosciences' median Gross Margin value was 99.01% (recorded in 2019), while the average stood at 99.0%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 5400bps in 2019, then crashed by -3700bps in 2021.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Gross Margin stood at 99.2% in 2017, then fell by 0bps to 98.83% in 2018, then grew by 0bps to 98.96% in 2019, then dropped by 0bps to 98.96% in 2020, then dropped by 0bps to 98.58% in 2021.
  • Its Gross Margin stands at 98.58% for Q3 2021, versus 98.93% for Q2 2021 and 98.77% for Q1 2021.